ONCT Oncternal Corp: Nilai Akuntansi saben Saham

Oncternal Therapeutics (ONCT) maintains a strong reputation for developing targeted antibodies against metastases, focusing on underserved segments of solid and hematologic tumor treatments. The book value per share reflects a trend of asset accumulation, with the 3.08 mark characterizing this parameter. The company specializes in combating rare cancers by blocking stem cell proteins to prevent relapses.

ONCT - Nilai Buku Siji Saham Oncternal Therapeutics Inc ing rentang 04.07.2022 - 14.12.2024

Ringkesan rincian data analitis oncternal.com (ONCT)

- rega lan prakiraan konsensus rega:

Rega saham Oncternal|ONCT - Target konsensus

- data kapitalisasi pasar:

Biji pasar Oncternal Therapeutics, Inc.|ONCT - Total Nilai Bisnis

- data kapitalisasi buku:

Nilai Buku saben Saham Oncternal Therapeutics|ONCT - Nilai Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku oncternal.com|ONCT - Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas Oncternal Therapeutics|ONCT - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Oncternal Therapeutics, Inc.|ONCT - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Oncternal Therapeutics, Inc.

Pambiji fundamental perusahaan:ONCT Oncternal

For Oncternal Therapeutics (ONCT), whose success depends on clinical trials rather than economic cycles, net asset dynamics reflect the real value of capital. By analyzing the estimated BVPS, an investor can see the company's residual value per share after deducting all liabilities, which allows for an assessment of resource management efficiency amid the Fed's tight monetary policy.

Pesaing Oncternal Therapeutics (ONCT)